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Despite high physiological variations in absolute serum concentra-
tions, the distribution of IgG subclasses within total serum IgG in
healthy persons is strictly adjusted to 60–70% IgG1, 20–30%
IgG2, 5–8% IgG3, and 0.7–4% IgG4. In previous reports it was
shown that patients with malignant diseases of various tissue
origin exhibit a characteristic and highly significant alteration in
the subclass composition of serum IgG, consisting in a reduction
in %IgG1 and an increase in %IgG2. This phenomenon has been
reported in patients suffering from carcinomas of the female breast
(Kronberger et al, 1994), various locations of the female reproduc-
tive tract (Schauenstein et al, 1996), and of the colo-rectal region
(Schauenstein et al, 1997), and it turned out to exhibit diagnostic
sensitivities and specificities comparable to, or – particularly at
early tumour stages – far higher than conventional serological
tumour markers. Patients with benign tumorous or inflammatory
diseases of the respective organs differed in their mean %IgG1 and
%IgG2 values from cancer patients with the same high signifi-
cance as did healthy controls.
Analogous results were obtained in experimental animal
models. In rats it was found that the transplantation of the Yoshida
hepatoma or Walker 256 carcinosarcoma cell lines led to an
identical IgG subclass shift affecting IgG2b and IgG2a (Weblacher
et al, 1993). The data obtained with this model revealed that this
tumour-associated phenomenon essentially requires the presence
of living, actively dividing tumour cells, that the shift becomes
significant long before an exponential tumour growth, and that it is
detectable also in the surface expression of the affected IgG
subclasses on peripheral blood B lymphocytes (Maninger et al,
1994).
In this study we present for the first time results of %IgG1 and
%G2 as obtained with patients suffering from squamous cell carci-
nomas of the head–neck region (SCC-HN). It should be noted that,
with this type of malignancy, until now no efficient conventional
serological marker has been available, particularly for the detec-
tion of post-therapeutic recurrences and/or metastases.
MATERIALS AND METHODS
Patients
A total of 81 patients were investigated after admission to the
Department of Otolaryngology of the University Hospital Graz,
consisting of 12 female (average age, 58) and 69 male patients
(average age, 60), all suffering from primary, histopathologically
verified SCC-HN. These patients were investigated as to %IgG1/
IgG2 prior to any treatment, except for diagnostic biopsy. Table 1
shows the distribution of the patients according to characteristics
of primary tumours (UICC TNM Classification of Malignant
Tumors, 1992). Seven of the patients with advanced tumours were
found afflicted with distant metastases.
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SummaryA significant decrease in %IgG1 accompanied by an increase in %IgG2 in total serum IgG has been previously reported as a highly
sensitive marker for detecting early stages of carcinomas of various localizations. Here we investigated the question as to whether this
phenomenon is also observed in sera of patients with squamous cell carcinoma of the head–neck region (SCC-HN), and to evaluate its
diagnostic performance in the post-operative monitoring. Using quantitative affinity chromatography, serum concentrations of IgG1, IgG2 and
total IgG were determined in 81 patients with different stages of primary and untreated SCC-HN, in 51 SCC-HN patients in post-therapeutical
follow up, and in 33 patients with organ matched benign diseases. The data were compared with a total of 174 healthy controls. It was found
that (i) 105 SCC-HN patients exhibited a mean value of 56.0 ±0.7% IgG1, which likewise differed from healthy controls (63.2 ±0.5) and
benign diseases (61.5 ±1.0) with P < 0.0005, (ii) sensitivities and specificities for discriminating primary malignancies from healthy controls
were 70 and 74% respectively, and from benign diseases 65 and 76%, (iii) highest sensitivities and specificities were observed with post-
therapeutic cases suffering from tumour recurrence (88% and 75%) or patients with distant metastases (87% and 86%), (iv) apparently
tumour-free post-therapeutic patients showed a mean %IgG1 not different from the normal value. The decrease in %IgG1 accompanied by
increased %IgG2 is an efficient, sensitive and early marker of SCC-HN, which appears particularly useful for the post-therapeutic monitoring.
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cancer patients who were in observation for 1–5 years after a
combined treatment consisting of radical surgery, irradiation with
an average dose of 60 Gy and a platin-based chemotherapy. These
patients were monitored by local inspection and sonography every
3 months of the first 2 post-operative years, and every 6 months
thereafter. Furthermore, they were examined once per year by
computer tomography or magnetic resonance for local recurrence,
as well as radiography of the thorax and sonography of the upper
abdomen for distant metastases. Any suspicious findings were
further investigated by biopsy and histological analysis. In 27
patients of this group no tumour could be detected (T0) at the time
of investigation, whereas 22 showed local recurrent disease. Five
patients of the latter group had developed distant metastases in
addition to local recurrence, two of the patients had distant metas-
tases only.
Finally, a total of 33 patients were included who were afflicted
with diverse benign diseases of the head and neck, such as chronic
infections of the paranasal sinuses, chronic tonsillitis, chronic
laryngitis and also lateral and/or median cysts of the neck. The
data of all these experimental groups were compared with the ones
of 174 healthy controls (both sexes, age matched).
Sampling
Blood (4–5 ml) taken from the forearm vein was allowed to clot
for 15 min and centrifuged at 3000 rpm. Since subclass IgG1 had
been shown earlier rapidly to form autoaggregates (Maninger et al,
1996) interfering with its detection, all determinations had to be
performed not later than 60 min after sampling.
Quantitation of subclasses IgG1, IgG2 and total IgG by
affinity chromatography
The method was recently described (Schauenstein et al, 1997). In
brief, 200 ml of serum was applied to a column (HiTrap, 1 ml,
Pharmacia, Uppsala, Sweden) filled with Protein A Sepharose
High Performance (Pharmacia, code-no. 17-0402-01); after
removal of all non-binding components with phosphate–citrate
buffer pH 7.0, IgG2 and IgG1 were sequentially eluted with the
same buffer, but with pH-values of 4.7 and 4.3 respectively. Total
IgG was eluted from a second serum aliquot (100 ml) with
glycine–HCl buffer, pH 2.7, after passage through a 1 ml HiTrap
column filled with Protein G Sepharose High Performance
(Pharmacia, code-no. 17-0404-01). Protein concentrations in all
eluates were determined at 280 nm, using a specific extinction
coefficient for IgG, e¢ of 1.58 [1000 g–1 cm2] (Schauenstein et al,
1986).
Statistical analysis
Single values obtained with all experimental groups and healthy
controls showed normal distributions, as shown in Figure 1, for
primary cancer patients vs. healthy controls. Accordingly, signifi-
cances of the differences between mean values were calculated
with the two-sided Student’s t-test, and cut-off values were calcu-
lated as the arithmetic means of mean values obtained from two
groups to be compared. Diagnostic sensitivities and specificities
were defined as percentages of patients with %IgG1 smaller, and
of healthy controls with %IgG1 greater than the cut-off value
respectively. ROC plots were calculated with the LABROC 1
program by Charles E Metz, Department of Radiology, The
University of Chicago, 5841 South Maryland Avenue, Chicago, 
IL 60637–1470, USA.
RESULTS
Table 2 summarizes the results obtained with patients carrying
primary SCC-HN and with the cases in the post-therapeutic
monitoring. The result is analogous to those previously reported
for carcinomas of other localizations, i.e. a significant decrease in
%IgG1 accompanied by an increase in %IgG2 within total IgG, as
compared with benign diseases or healthy controls. Also in accor-
dance with previous experiences, the tumour-associated changes
in %IgG1 and %IgG2 were quantitatively not very high yet of
highest significance, which is due to both the small biological
variations of relative IgG1 and G2 mean values and the high
accuracy of measurements (interassay variations of ±1–2%). No
quantitative dependence on size and extent was observed with
primary tumours, hence cases with T1 tumours exhibited the same
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Table 1 Distribution of patients with primary tumours according to tumour
burden
Tumour diameter n
T1 tumour restricted to one area ≤ 2c m 1 8
T2 tumour in more than one area; 2–4 cm 19
in carcinomas of the larynx: no
fixation of the vocal cord
T3 tumour diameter > 4 cm or fixation > 4 cm 13
of vocal cord or hemilarynx in carcinomas
of the larynx and hypopharynx
T4 tumour exceeding organ borders, infiltrating 31
neighbouring structures
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Figure 1 Statistical distributions of single values of %IgG1,
pretherapeutically determined in sera of 74 patients with SCC-HN (T1–T4),
compared with 174 healthy controlssignificance as more advanced stages. In contrast, secondary
disease consisting in local recurrence or distant metastasis showed
a clear-cut increase in the effect, which is reflected in increased
sensitivities and specificities (Table 3).
The histograph in Figure 1 shows the normal distributions of the
single values of %IgG1 of healthy controls and primary tumour
patients, which allows calculation of cut-off values, sensitivities
and specificities as described in the Methods section. Identical
distributions were seen with the other groups investigated (not
shown). The sensitivity and specificity of %IgG1 for diagnosing
SCC-HN are illustrated as ROC-plot in Figure 2. A clear-cut
increase in the diagnostic performance is observed from primary
tumours to local recurrences and metastatic disease. This quantita-
tive dependence is also expressed with the second parameter, i.e.
the increase in %IgG2, as shown in Figure 3. While no quantitative
differences in the IgG1/G2 shift were noted between primary
tumours of different stages (not shown), the decrease in %IgG1
and increase in %IgG2 became most obvious with local recur-
rences and distant metastases.
DISCUSSION
SCC-HN predominantly affects males, whereby a variety of envi-
ronmental irritants have been implicated, notably cigarette smoke
(Maran et al, 1993). As head and neck cancers in general are easily
accessible to inspection and tissue sampling, serological tumour
markers are not of great relevance to the primary diagnosis in most
of the cases (Dreyfuss et al, 1992). Thus, the primary need for a
serological marker in head and neck cancer is certainly in the post-
therapeutic monitoring, i.e. the early and sensitive diagnosis of
local recurrence, and of distant metastases (Dreyfuss et al, 1992;
Gleich et al, 1996), e.g. in lung, liver or bone, where tissue
sampling is often not possible or dangerous. The criteria that
should be met by a reliable and useful tumour marker are (Clasen
et al, 1988): (i) a high sensitivity to early tumour stages, (ii) a high
specificity for malignant growth, (iii) an easy and reproducible
evaluation in daily routine practice, and (iv) the test should be
rapid and inexpensive. Until now numerous tumour-derived
substances have been evaluated as diagnostic indicators of tumour
presence in untreated patients, but, with few exceptions, most of
these direct markers proved to be only of limited clinical useful-
ness owing to extremely high biological variabilities, limited
specificities for malignant proliferation, and low sensitivities for
detecting early tumour stages. Particularly for SCC-HN no suffi-
ciently sensitive non-invasive tumour marker was available until
now (Fischbach et al, 1990). Squamous cell carcinoma antigen
(SCC-A) was considered a promising candidate in aiding diag-
nosis and monitoring of patients with SCC-HN, but the diagnostic
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Table 2 %IgG1 and %IgG2 in total serum IgG, obtained with patients suffering from untreated primary SCC-HN, local recurrence or distant
metastases respectively, cured tumour-free patients and cases of benign diseases of the HN region, in contrast to healthy controls
Probands n mg IgG ± s.e.m. %IgG1 ±s.e.m. %IgG2 ±s.e.m.
All cancer patients 105 10 0.3 56a 0.7 24.4a 0.7
Primary untreated SCC-HN (T1–T4) 74 9.6 0.4 56.8a 0.9 23.4d 0.9
Primary SCC-HN with distant metastases 7 12.5 0.5 54.6a 1.3 25.4f 1.4
Primary SCC-HN (T1) 18 8.4 0.6 55.9a 1.1 23.3e 1.6
Local recurrence 16 10.4 1 54.9a 1.4 26.8d 2
Local recurrence with distant metastases 6 11 1.2 49.6a 3.3 30.5d 2.8
Distant metastases without primary tumour
or local recurrence 2 13.9 48.9 31
All patients with distant metastases 15 11.4 0.6 52.9a 1.5 27.2d 1.4
Post-operative tumour-free (T0) 27 8.4 0.5 61.9 0.9 23.9 1.5
Benign diseases 33 8.4 0.4 61.5b,c 12 1 g,h 1.2
Healthy controls 174 10.3 0.2 63.2 0.5 20.4 0.5
aDifferent from healthy controls (P < 0.0005). bDifferent from malignant cases (P < 0.0005). cDifferent from primary untreated SCC-HN 
(P = 0.0005). dDifferent from healthy controls (P = 0.0005). eDifferent from healthy controls (P = 0.05). fDifferent from healthy controls 
(P = 0.0025). gDifferent from malignant cases (P = 0.01). hDifferent from primary untreated SCC-HN (P = 0.05).
Table 3 Sensitivities and specificities obtained with %IgG1, discriminating SCC-HN from healthy controls or
benign diseases
vs. Healthy controls vs. Benign diseases
Probands Sensitivity Specificity Sensitivity Specificity
All cancer patients 75 78 70 76
Primary untreated SCC-HN 70 74 65 76
Local recurrence 88 75 69 79
Patients with distant metastases 87 86 80 82performance finally turned out to be poor. SCC-A was described to
be elevated (> 2 ng ml–1) in 12–15% (Walther et al, 1990), 28%
(Clasen et al, 1988), 33% (Dreyfuss et al, 1992), 38% (Fischbach
et al, 1990; Koch et al, 1989) or 44% (Eibling et al, 1989) of SCC-
HN patients. These results are in good agreement with our own
unpublished experiences, where only 26% of a total of 322 SCC-
HN patients were found to be positive. Other serological markers,
such as platelet-derived growth factor (PDGF) or carcino-
embryonic antigen (CEA) did fail as screening markers for
primary SCC-HN. They may be useful, perhaps, in combination
with other markers for monitoring purposes (Gleich et al, 1996;
Silverman et al, 1976).
The present data suggest the changes in %IgG1 and %IgG2 as a
useful serological tumour marker for detecting primary or recur-
rent and/or metastatic SCC-HN. It should be stressed once more
that it is the specific alteration of the subclass pattern, independent
from absolute quantitative changes of total serum IgG, that gives
the relevant and highly sensitive information. Diagnostic sensitiv-
ities and specificities were so far calculated on the bases of the
change in %IgG1 only. A bivariate analysis including %IgG2 may
further enhance the discriminating efficiency.
Concerning the specificity of the IgG subclass shift for malig-
nant proliferation, it is stated that a similar change in the relative
concentrations of IgG1 and IgG2 has not been described with 
any other pathological condition. Patients afflicted with benign
diseases (benign tumours or inflammations) of the tissues so far
investigated sometimes showed a similar trend (Kronberger et al,
1994; Schauenstein et al, 1996; Schauenstein et al, 1997), but
consistently differed from cancer patients with the same level of
significance as did healthy controls. Even though our experience at
present does not indicate any significant association of the
IgG1/G2 shift with other common diseases, further studies are
under way to examine this parameter in selected immunopatho-
logical conditions.
Whereas conventional serological markers directly correspond
to tumorigenic products, the shift in %IgG1/G2 represents an
indirect marker, consisting in a change of the host’s immune
system due to the presence of malignant tumours. Evidence for
this notion has first been obtained in the rat model where, in
parallel to the change in IgG subclass serum proteins, a similar
shift was detected in the distribution of surface expressed IgG
subclasses on B cells in the peripheral blood (Maninger et al,
1994). This suggests that the presence of a malignant process
interferes with the regulation of the biosynthesis of IgG subclasses
at the B-lymphocyte level. Very recent preliminary data obtained
with a quantitative reverse transcriptase polymerase chain reaction
to detect IgG1 and IgG2 specific mRNA suggest that the same
may be true in humans. Peripheral blood lymphocytes of patients
suffering from gynaecological malignancies were found to exhibit
a drastically reduced ratio in the messages for IgG1 vs IgG2, as
compared with healthy controls (Felsner et al, submitted for publi-
cation). Experiments are presently under way to examine the
hypothesis that malignant tumours may modulate the IgG subclass
biosynthesis by the expression of certain cytokines and/or their
soluble receptors, which are involved in IgG subclass regulation
(Kawano et al, 1994). Whatever the mechanisms are, the regula-
tion of IgG subclasses apparently is extremely sensitive to respec-
tive signals derived from malignant cells, which is reflected by the
high sensitivity of the phenomenon, particularly for early stages of
various tumours in humans (Kronberger et al, 1994; Schauenstein
et al, 1996, 1997) including SCC-HN (see present data), and in the
rat model (Weblacher et al, 1993). An attractive feature of the IgG
subclass shift as tumour marker are the extremely small variation
ranges of the single values in normal controls and tumour patients,
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Figure 2 ROC plots (sensitivities vs. specificities), obtained with %IgG1,
comparing 105 malignant cases of SCC-HN with healthy controls and with
33 cases of benign diseases, and 22 cases with recurrent SCC-HN and
23 cases with distant metastases with healthy controls
Figure 3 Mean values of %IgG2 (ordinate) and of %IgG1 (abscissa) with
the respective s.e.m., obtained with 174 healthy controls (1), 33 benign cases
of the HN-region (2), 23 tumour free post-therapeutic patients T0 (3), 74
cases with primary, untreated SCC-HN, all stages (4), 16 patients with
recurrent SCC-HN (5) and 15 patients with distant metastases (6)as compared with several orders of magnitude often observed with
conventional tumour markers. This fact, together with the normal
distributions of the single values allows for simple statistical
evaluations, without logarithmic transformation or non-parametric
tests.
Until now the shift in %IgG1/G2 was reported as a phenomenon
occurring with tumours of various tissue origin. In the framework
of the present study, an apparent specificity for squamous cell
carcinoma emerged, as a group of patients (n = 13) suffering from
head and neck tumours of other histopathological types, including
large cell carcinoma, adenocarcinoma, poorly differentiated
carcinoma, cylindrical cell carcinoma, and malignant lymphoma,
exhibited mean values for %IgG1 of 64 ± 1.5 and for %IgG2 of
18.0 ± 1.5, which are both clearly in the normal range. Further
studies are needed to confirm this finding, and to delineate further
the specificities of the phenomenon for different tumours derived
from other tissues.
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